AB
CLYM

Amalgamated Bank’s Climb Bio CLYM Stock Holding History

Amalgamated Bank’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,016
Closed -$1K – 3180
2025
Q1 		$1K Buy
1,016
+764
+303% +$1.24K ﹤0.01% 2947
2024
Q4 		$0 Hold
252
– – ﹤0.01% 2986
2024
Q3 		$1K Hold
252
– – ﹤0.01% 2983
2024
Q2 		$2K Buy
+252
New +$1.68K ﹤0.01% 2971
2022
Q2 		– Sell
-1,039
Closed -$9K – 3230
2022
Q1 		$9K Buy
+1,039
New +$9.69K ﹤0.01% 2980

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Amalgamated Bank's CLYM Position: Q2 2025 in Review

Amalgamated Bank sold out of Climb Bio (CLYM) in Q2 2025, closing a stake of 1,016 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in CLYM in Q1 2022 and held it in 5 quarters. The position peaked at $9K in Q1 2022. 69 funds tracked by Wall St. Rank hold CLYM as of Q2 2025.

  • Amalgamated Bank reported no remaining Climb Bio position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 1,016 Climb Bio shares in Q2 2025, an estimated $1K.
  • Amalgamated Bank first reported a position in Climb Bio in Q1 2022 and held it in 5 quarters.
  • Amalgamated Bank's Climb Bio position peaked at $9K in Q1 2022.
  • 69 funds tracked by Wall St. Rank held Climb Bio as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.